BGM Group Had to Hold the Same Shareholder Vote Twice. Cayman Law Is Why.

The strange part isn't that BGM Group held an extraordinary shareholder meeting. It's that the company had to hold the same one twice.

On September 5, shareholders of BGM Group (Nasdaq: BGM) — a Cayman Islands company run out of Chengdu that sells AI insurance services and generic pharma ingredients — voted to undo the share overhaul they had already approved at a July 9 meeting, then approve it again with the numbers filled in. Of 400,623,358 ordinary shares outstanding, holders representing 273,457,527 of them, about 68%, turned up. Every resolution passed.

That is weird. The basic point is that BGM's recapitalization ran into a rule about who is allowed to change a company's share capital, and the rule does not bend.

Under Cayman corporate law, the things that actually alter share capital — consolidating many shares into fewer, cutting or raising the amount of authorized capital a company is allowed to hold — are powers reserved to shareholders themselves, acting by special resolution. You cannot vote a blank check and tell the board to sort out the details later. In BGM's telling, Cayman authorities clarified that members cannot delegate share capital alterations to directors, which is how the company ended up scrapping its July vote and running the whole thing again with the specific terms put straight to shareholders.

What shareholders approved the second time around: revoking the July resolutions, a 30-for-1 share consolidation, restoring authorized capital to 5 billion Class A shares, and adopting a fifth amended memorandum and articles of association.

The reason for the exercise is old-fashioned, and it has nothing to do with the AI platform. BGM is a penny stock. The shares changed hands around $0.27 this week, a price in penny-stock territory. In April, Nasdaq informed the company it had failed the $1.00 minimum bid-price requirement for continued listing and gave it until October 21, 2026, to close at $1.00 or higher for ten consecutive trading days. A 30-for-1 reverse split is the blunt, time-tested fix: at roughly $0.27, it would lift the price to roughly $8, comfortably above the threshold, while cutting the share count from about 400 million to about 13.4 million and leaving the market value untouched. Reverse splits to dodge a delisting notice are among the oldest moves in the market, and this is one of them.

The consolidation is the headline. The number worth actually watching is the other one: authorized capital of 5 billion Class A shares.

Authorized capital is the ceiling on how many shares a company can issue without going back to shareholders for permission. After a 30-for-1 split leaves about 13.4 million shares outstanding, authorizing 5 billion means the company has room for more than 350 shares of potential future issuance for every single share trading today. That is not a rounding number; it is a funding machine.

The consolidation is about optics — keeping the listing alive. The authorized-capital reset is about room to raise money, and room to raise money is, for whoever holds the shares today, room to be diluted. BGM has already said the quiet part in its own filings: in May it warned existing shareholders to expect "meaningful" and "substantial" dilution. It has spent 2026 juggling Nasdaq on two separate fronts — a February notice over a late annual report and the April notice over the share price.

The hard part is structural, and I'm fairly sure of it: the split solves the $1 problem on paper, and the roughly $8 opening price leaves plenty of runway for the ten-day clock. The part you can't see on the tape is how much of those 5 billion authorized shares actually get issued, and at what prices. That is the real question the EGM only answered on paper. The shareholders approved the machinery on September 5; the machinery now just needs to be fed. In a stock like this, that usually means someone else's shares.